论文部分内容阅读
目的 对采用改良方法自行制备抗肿瘤药物磁性白蛋白微球阿霉素进行定性研究和评价。方法 采用改良方法自行制备抗肿瘤药物磁性白蛋白微球阿霉素 ,并经细胞图像分析仪二值化处理 ,优选出符合静脉用药的最佳磁微球 (0 .91± 0 .3 3 ) μm ,并以小鼠和豚鼠为实验对象 ,对该复合物进行定性分析 ,观察 (长达 6周 )该复合药物的急性、亚急性等毒性实验 ,并作相应的病理学检查。同时 ,测定其LD50 值。结果 该复合药物对实验动物的组织细胞并没有毒性损伤 ,也没有在体内蓄积。其LD50 值为 2 3 .3mg/kg体重 ,高于单纯阿霉素静脉给药的LD50 值 (2 0 .0mg/kg体重 )。结论 该复合物毒性很小 ,具有可靠的安全性 ,并优于单纯阿霉素。
OBJECTIVE To qualitatively study and evaluate the preparation of the anti-tumor drug magnetic albumin microsphere doxorubicin by an improved method. Methods The modified magnetic nanoparticles microspheres doxorubicin was prepared by modified method. The best magnetic microspheres (0.91 ± 0.33) were obtained by binary image analysis. μm, and the mice and guinea pigs were used as experimental subjects. Qualitative analysis of the complex was performed to observe the acute and subacute toxicity of the combination drug (up to 6 weeks) and the corresponding pathological examination. At the same time, determine its LD50 value. Results The composite drug has no toxic damage to the tissue cells of experimental animals and does not accumulate in the body. The LD50 value was 23.3 mg / kg body weight, which was higher than the LD50 value of intravenous doxorubicin administration alone (2.0 mg / kg body weight). Conclusion The complex is less toxic, has reliable safety and is superior to doxorubicin alone.